Dexmedetomidine, fentanyl and magnesium sulphate as adjuvants to 0.5% hyperbaric bupivacaine

Comparative study of intrathecal dexmedetomidine, fentanyl and magnesium sulphate as adjuvants to 0.5% hyperbaric bupivacaine for knee arthroscopic surgeries.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202501636694793

Enrollment

Registered

2025-01-15

Start date

2024-11-11

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Orthopaedics Anaesthesia

Interventions

Group I

Group II

Group III

Group IV

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The study was conducted on 60 patients of ASA I or II, between 21 and 40 years of age scheduled for knee arthroscopic surgeries.

Exclusion criteria

Exclusion criteria: -Patient's refusal. -Patients with: -Morbid obesity. -Cardiac diseases. -Hepatic diseases. -Renal disease. -Diabetes mellitus. -Coagulation disorders. -ASA III-IV. -Hypertensive patients.

Design outcomes

Primary

Measure	Time frame
Assessment of the onset and duration of analgesia and sensory and motor blockade	—

Secondary

Measure	Time frame
study the hemodynamic effects and postoperative analgesic requirement in the knee arthroscopic surgeries	—

Countries

Egypt

Contacts

Public ContactMahmoud Abdelsalam

Lecturer in Anesthesiology

dreamobeng@gmail.com201008223320

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026